Hologic price target lowered to $70 from $77 at Stephens

Stephens lowered the firm’s price target on Hologic (HOLX) to $70 from $77 and keeps an Overweight rating on the shares. Shares traded down after a “disappointing” fiscal Q2 report, notes the analyst, who thinks a lack of catalysts could keep shares range bound in the near-term. However, at the current valuation, the firm feels moderated near-term growth is priced in and thinks there’s likely more upside than downside over the next 12 months, but this relies on execution in breast health, the analyst tells investors.